Omega-3、Omega-6及总膳食多不饱和脂肪酸用于2型糖尿病预防与治疗:随机对照试验的系统综述与Meta分析
该系统综述与Meta分析纳入83项至少24周的随机对照试验,评估增加Omega-3、Omega-6及总多不饱和脂肪酸(PUFA)对糖尿病诊断和糖代谢的影响。长链Omega-3对糖尿病诊断(RR 1.00,95%CI 0.85至1.17)及糖代谢指标均无显著影响;α-亚麻酸、Omega-6及总PUFA对糖尿病诊断的影响因证据质量极低而不明确,对糖代谢指标影响很小或无影响,但增加α-亚麻酸可能使空腹胰岛素升高约7%。
要点
- 长链Omega-3对糖尿病诊断及糖代谢指标无显著影响。
- 补充长链Omega-3剂量高于4.4 g/d时观察到阴性结局的提示。
- α-亚麻酸、Omega-6及总PUFA对糖尿病诊断的影响不明确。
核心结论
- 证据提示增加Omega-3、Omega-6或总PUFA对2型糖尿病的预防和治疗影响很小或无影响。
- 这是迄今评估多不饱和脂肪酸对新诊断糖尿病和糖代谢影响的最广泛系统综述,包括联系作者后获得的既往未发表数据。
研究设计与样本
- 系统综述与Meta分析,检索Medline、Embase、Cochrane CENTRAL、WHO国际临床试验注册平台、Clinicaltrials.gov及相关系统综述中的试验。
- 纳入至少24周的随机对照试验,评估增加α-亚麻酸、长链Omega-3、Omega-6或总PUFA,并收集糖尿病诊断、空腹血糖或胰岛素、糖化血红蛋白(HbA1c)和/或胰岛素抵抗稳态模型评估(HOMA-IR)数据。
- 共纳入83项随机对照试验(主要评估补充长链Omega-3),其中10项为低偏倚风险总结。
- 采用随机效应Meta分析(相对风险和均数差)及敏感性分析,检查漏斗图,并按干预类型、替代、基线糖尿病风险、抗糖尿病药物使用、试验时长和剂量进行亚组分析。
- 使用Cochrane工具评估偏倚风险,使用GRADE评估证据质量。
主要发现
- 长链Omega-3对糖尿病诊断可能性影响很小或无影响(相对风险1.00,95%置信区间0.85至1.17;58 643名参与者,3.7%发生糖尿病)。
- 长链Omega-3对糖化血红蛋白(均数差-0.02%,95%置信区间-0.07%至0.04%)、血浆葡萄糖(0.04,0.02至0.07 mmol/L)、空腹胰岛素(1.02,-4.34至6.37 pmol/L)和HOMA-IR(0.06,-0.21至0.33)影响很小或无影响。
- 补充长链Omega-3剂量高于4.4 g/d时观察到阴性结局的提示。
- α-亚麻酸、Omega-6及总PUFA对糖尿病诊断的影响不明确(证据质量极低),但对糖代谢指标影响很小或无影响,例外是增加α-亚麻酸可能使空腹胰岛素升高约7%。
- 未发现证据表明Omega-3/Omega-6比值对糖尿病或糖代谢重要。
关键数值与推荐
- 长链Omega-3对糖尿病诊断:相对风险1.00(95%置信区间0.85至1.17),58 643名参与者中3.7%发生糖尿病。
- 长链Omega-3对糖化血红蛋白:均数差-0.02%(95%置信区间-0.07%至0.04%)。
- 长链Omega-3对血浆葡萄糖:均数差0.04(95%置信区间0.02至0.07)mmol/L。
- 长链Omega-3对空腹胰岛素:均数差1.02(95%置信区间-4.34至6.37)pmol/L;对HOMA-IR:均数差0.06(95%置信区间-0.21至0.33)。
- 补充长链Omega-3剂量高于4.4 g/d时观察到阴性结局的提示;增加α-亚麻酸可能使空腹胰岛素升高约7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- α-亚麻酸、Omega-6及总PUFA对糖尿病诊断影响的证据质量极低。
- 83项试验中仅10项为低偏倚风险总结。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess effects of increasing omega-3, omega-6, and total polyunsaturated fatty acids (PUFA) on diabetes diagnosis and glucose metabolism. DESIGN: Systematic review and meta-analyses. DATA SOURCES: Medline, Embase, Cochrane CENTRAL, WHO International Clinical Trials Registry Platform, Clinicaltrials.gov, and trials in relevant systematic reviews. ELIGIBILITY CRITERIA: Randomised controlled trials of at least 24 weeks' duration assessing effects of increasing α-linolenic acid, long chain omega-3, omega-6, or total PUFA, which collected data on diabetes diagnoses, fasting glucose or insulin, glycated haemoglobin (HbA1c), and/or homoeostatic model assessment for insulin resistance (HOMA-IR). DATA SYNTHESIS: Statistical analysis included random effects meta-analyses using relative risk and mean difference, and sensitivity analyses. Funnel plots were examined and subgrouping assessed effects of intervention type, replacement, baseline risk of diabetes and use of antidiabetes drugs, trial duration, and dose. Risk of bias was assessed with the Cochrane tool and quality of evidence with GRADE. RESULTS: 83 randomised controlled trials (mainly assessing effects of supplementary long chain omega-3) were included; 10 were at low summary risk of bias. Long chain omega-3 had little or no effect on likelihood of diagnosis of diabetes (relative risk 1.00, 95% confidence interval 0.85 to 1.17; 58 643 participants, 3.7% developed diabetes) or measures of glucose metabolism (HbA1c mean difference -0.02%, 95% confidence interval -0.07% to 0.04%; plasma glucose 0.04, 0.02 to 0.07, mmol/L; fasting insulin 1.02, -4.34 to 6.37, pmol/L; HOMA-IR 0.06, -0.21 to 0.33). A suggestion of negative outcomes was observed when dose of supplemental long chain omega-3 was above 4.4 g/d. Effects of α-linolenic acid, omega-6, and total PUFA on diagnosis of diabetes were unclear (as the evidence was of very low quality), but little or no effect on measures of glucose metabolism was seen, except that increasing α-linolenic acid may increase fasting insulin (by about 7%). No evidence was found that the omega-3/omega-6 ratio is important for diabetes or glucose metabolism. CONCLUSIONS: This is the most extensive systematic review of trials to date to assess effects of polyunsaturated fats on newly diagnosed diabetes and glucose metabolism, including previously unpublished data following contact with authors. Evidence suggests that increasing omega-3, omega-6, or total PUFA has little or no effect on prevention and treatment of type 2 diabetes mellitus. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42017064110.
引用
- Brown TJ, Brainard J, Song F, et al. Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019. PMID: 31434641. doi:10.1136/bmj.l4697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。